Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy. 2008 26:2384–9.īrown CE, Alizadeh D, Starr R, Weng L, Wagner JR, Naranjo A, et al. Prognostic Factors in Metastatic Rhabdomyosarcomas: Results of a Pooled Analysis From United States and European Cooperative Groups. Oberlin O, Rey A, Lyden E, Bisogno G, Stevens MCG, Meyer WH, et al. Therefore, targeting αvβ3 and HER2 using a bispecific CAR-T approach may be effective for RMS. HER2 is known to be expressed on RMS, and one child with RMS experienced a temporary remission with HER2-CAR-T. We previously established the efficacy of alpha 5beta 3 (αvβ3) and HER2 CAR-Ts against diffuse intrinsic pontine glioma/glioblastoma and medulloblastoma, respectively. We hypothesize that simultaneously targeting two RMS antigens with a bispecific CAR-T will provide a new treatment modality while reducing the likelihood of antigen escape. Therefore, more effective treatments are desperately needed.Ĭhimeric antigen receptor T-cell (CAR-T) therapy has been highly successful for relapsed/refractory hematologic malignancies, but antigen downregulation by tumors have not uncommonly led to immunotherapy escape across several platforms. Background Even though rhabdomyosarcoma (RMS) is the most prevalent sarcoma in children, therapy relies on decades-old, multi-agent chemotherapy, radiation and surgery, which are ineffective in the salvage or metastatic disease setting, with only 30% of patients surviving three years.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |